NOVARTIS AG-REG (NOT.DE) Stock Price, Forecast & Analysis
FRA:NOT • CH0012005267
NOT.DE Key Statistics, Chart & Performance
The current stock price of NOT.DE is 135.76 EUR. In the past month the price increased by 7.46%.
NOT.DE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to NOT.DE.
NOT.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to NOT.DE. NOT.DE has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
NOT.DE Financial Highlights
Over the last trailing twelve months NOT.DE reported a non-GAAP Earnings per Share(EPS) of 7.55. The EPS increased by 14.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 24.83% | ||
| ROA | 12.6% | ||
| ROE | 30.31% | ||
| Debt/Equity | 0.64 |
NOT.DE Forecast & Estimates
32 analysts have analysed NOT.DE and the average price target is 126.69 EUR. This implies a price decrease of -6.68% is expected in the next year compared to the current price of 135.76.
For the next year, analysts expect an EPS growth of 3.87% and a revenue growth 2.69% for NOT.DE
NOT.DE Ownership
NOT.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SAN | SANOFI | 9.36 | 199.406B | ||
| SNW | SANOFI | 9.39 | 199.357B | ||
| 1SAN | SANOFI | 9.76 | 199.188B | ||
| MRK | MERCK KGAA | 14.59 | 54.5B | ||
| 1MRK | MERCK KGAA | 14.2 | 53.065B | ||
| UCB | UCB SA | 26.61 | 51.351B | ||
| UNC | UCB SA | 26.19 | 51.195B | ||
| 1BAYN | BAYER AG-REG | 9.42 | 45.329B | ||
| BAYN | BAYER AG-REG | 9.35 | 45.314B | ||
| IPN | IPSEN | 12.94 | 11.633B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About NOT.DE
Company Profile
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,883 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Company Info
NOVARTIS AG-REG
Lichtstrasse 35
Basel BASEL-STADT CH
Employees: 75883
Phone: 41613241111
NOVARTIS AG-REG / NOT.DE FAQ
Can you describe the business of NOVARTIS AG-REG?
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,883 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
What is the stock price of NOVARTIS AG-REG today?
The current stock price of NOT.DE is 135.76 EUR. The price increased by 2.08% in the last trading session.
Does NOT stock pay dividends?
NOVARTIS AG-REG (NOT.DE) has a dividend yield of 3.1%. The yearly dividend amount is currently 3.4.
What is the ChartMill technical and fundamental rating of NOT stock?
NOT.DE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the Price/Earnings (PE) ratio of NOVARTIS AG-REG (NOT.DE)?
The PE ratio for NOVARTIS AG-REG (NOT.DE) is 17.98. This is based on the reported non-GAAP earnings per share of 7.55 and the current share price of 135.76 EUR.
What is the next earnings date for NOT stock?
NOVARTIS AG-REG (NOT.DE) will report earnings on 2026-04-27.